More Videos
SPECIAL REPORT
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- European Commission Objects to Sun Micro-Oracle Deal
- Future of Marketing
- Mad Mail: Buy the Berkshire Hathaway Split?
- Cramer: 5 Stocks to Play the Next Bull Run
- JPMorgan Lifts Salary Freeze Amid Recovery
- Framed for Porn – By a PC Virus
- Israel: Leader of Business Innovation
- Maria's Market Message
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Yahoo Is in Expanding Mode, Hiring: CEO
- UK Most at Risk of Losing Top Credit Rating: Fitch
- New Lows for Stocks Next Year: Equities Bear
- GM CEO Starts Charm Tour at Opel in Germany
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Bad Debt Weighs on Barclays Earnings
- HSBC Operating Profit Beats, US Bad Debts Slip
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
RSS FEED
Pharma's Market
Text Size 
 |
I've had to permanently delete reports a few times already because the files are so big. So, I'm gonna stay away from all that here. Instead, I want to highlight what I think is one of the most interesting studies released last night. It's not really a needle-mover (at least, not yet) for the world's biggest drug company, Pfizer [PFE
Loading...
()
] , but it's definitely a good watercooler, talkabout item.
Pfizer markets a new stop-smoking pill Chantix which despite a recent psychiatric side-effect warning looks like it could be a blockbuster-in-the-making. But could it also have an unlikely, older product to offer smokers as well? Researchers at Houston's MD Anderson Cancer Center one of the nation's leading oncology hospitals, think so.
They put out this press release when the embargo lifted on all of the ASCO studies at 9 pm ET last night touting a study that shows Pfizer's painkiller Celebrex may help prevent lung cancer.
Doctors enrolled a couple hundred current and former smokers in the study and gave them two different doses of Celebrex. And especially among the current smokers who got the highest dose of Celebrex they report a decrease in "markers" for lung cancer. What's going on? In simple terms, the experts say there's something called a COX-2 enzyme that lives in tumors and that fuel their growth. Celebrex is a COX-2 inhibitor.
Celebrex is the only COX-2 inhibitor still for sale. Merck [MRK
Loading...
()
] pulled Vioxx and Pfizer pulled Bextra off the market a few years ago because of heart side effects. In fact, this study was stopped for awhile during the COX-2 safety scare, but later given a green light to resume once officials were comfortable Celebrex wouldn't hurt people. Indeed, the researchers report that they've seen no heart side effects in this approximately six-year study.
Dr. Waun Ki Hong is quoted in the press release as saying, "The Celebrex findings are exciting for the entire field of lung cancer chemoprevention." He and his colleagues will present updated data from the study, funded by the National Cancer Institute, at the ASCO meeting at the end of this month.
Celebrex sales took a hit during the Vioxx-Bextra recall fallout, but have been climbing back. Revenue was $2.3 billion last year, up from $2 billion in 2006, but still well below 2004's $3.3 billion (Vioxx was pulled at the end of the third quarter of that year.)
In a down market, PFE shares, as I write this, are back in the "teenager" category again.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes